Spotlighting Preclinical Modelling to Validate JJP‑1008 as a First‑in‑Class Anti‑CD270 Checkpoint Inhibitor
- Revealing CD270 as a key melanoma escape mechanism through tumour‑model–driven studies demonstrating that high CD270 expression is mutually exclusive with PD‑L1 and strongly associated with resistance to PD‑1/PD‑L1 inhibitors
- Demonstrating robust immunostimulatory activity of JJP‑1008 in in vitro models and humanized melanoma models (CDX/NOG), where repeated dosing inhibited aggressive tumour growth, reduced cachexia, and increased CD4⁺/CD8⁺ T‑cell infiltration—shifting the microenvironment from immunosuppression to activation
- Elucidating JJP‑1008’s selective blockade of immunosuppressive HVEM signals (BTLA/CD160) while preserving LIGHT‑mediated co‑stimulation, offering a novel mechanism to restore antitumour immunity and enhance model‑based evaluation of next‑generation immunotherapies